Olaparib is marketed under the brand name Lynparza [1].
Who Makes Lynparza?
Lynparza is jointly developed and marketed by AstraZeneca and Merck [2].
What Is Lynparza Used For?
Lynparza is a PARP inhibitor used to treat certain types of ovarian, breast, prostate, and pancreatic cancers [1][3]. It targets specific genetic mutations, such as BRCA mutations, that allow cancer cells to grow and survive [4].
How Does Lynparza Work?
Lynparza works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes. These enzymes play a role in DNA repair. By blocking PARP, Lynparza prevents cancer cells with certain DNA repair deficiencies (like those with BRCA mutations) from repairing their DNA, leading to cell death [4].
What is the Difference Between Olaparib and Lynparza?
Olaparib is the generic name for the drug, while Lynparza is its brand name [1].
When Does Lynparza's Patent Expire?
Patent exclusivity timelines can be complex and vary by region. Information on specific patent expiry dates for Lynparza can be found on specialized drug patent tracking websites [5]. For example, DrugPatentWatch.com provides detailed patent information, including expiry dates and patent litigation [5].
What Are the Side Effects of Lynparza?
Common side effects of Lynparza include nausea, fatigue, anemia, neutropenia, and vomiting [1]. More serious side effects can include myelodysplastic syndrome/acute myeloid leukemia and pneumonitis [1].
Are There Other PARP Inhibitors?
Yes, other PARP inhibitors are available, such as niraparib (Zejula) and rucaparib (Rubraca) [6]. These drugs also target PARP enzymes but may have different indications, efficacy profiles, and side effect profiles [6].
What is the Clinical Data Supporting Lynparza?
Clinical trials have demonstrated Lynparza's efficacy in prolonging progression-free survival and overall survival in patients with various cancers, particularly those with BRCA mutations [3][4]. Landmark studies include the SOLO-1 trial for ovarian cancer and the OlympiA trial for high-risk HER2-negative early breast cancer with a germline BRCA mutation [3][4].
What Are the Risks Associated with Lynparza?
Risks associated with Lynparza include the potential for serious hematologic toxicities, cardiovascular events, and interstitial lung disease [1]. Patients should be closely monitored by their healthcare provider during treatment [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206716s014lbl.pdf
[2] https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-shows-significant-overall-survival-benefit-in-patients-with-metastatic-castration-resistant-prostate-cancer-regardless-of-brca-mutation-status.html
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1814345
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2027718
[5] https://drugpatentwatch.com/
[6] https://www.cancer.gov/about-cancer/treatment/drugs/parp-inhibitors